ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Myeloma in Taipei City

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Lymphoma
Hematologic Cancer
Cancer
Leukemia
Smoldering Multiple Myeloma
Non-Hodgkin Lymphoma

Multiple Myeloma trials near Taipei City, TWN:

A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

(DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple...

Active, not recruiting
Multiple Myeloma
Drug: Lenalidomide
Drug: Daratumumab

Phase 3

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Taipei, Taiwan and 145 other locations

doses) of the study medicine (elranatamab) in participants with multiple myeloma that has come back after responding to treatment o ...

Active, not recruiting
Multiple Myeloma
Drug: Elranatamab

Phase 2

Pfizer
Pfizer

Taipei City, Taiwan and 41 other locations

of belantamab (bela) in participants with relapsed or refractory multiple myeloma (RRMM).* Part 2: The primary purpose of this part...

Enrolling
Multiple Myeloma
Drug: Belamaf
Drug: Standard of Care

Phase 1

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Taipei, Taiwan and 16 other locations

Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spon...

Enrolling
Multiple Myeloma
Drug: Bortezomib
Drug: Elotuzumab

Phase 3

AbbVie
AbbVie

Taipei City, Taiwan and 4 other locations

monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Pa...

Enrolling
Multiple Myeloma
Drug: Elranatamab
Drug: Lenalidomide

Phase 3

Pfizer
Pfizer

Taipei, Taiwan and 210 other locations

Locations recently updated

with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple...

Enrolling
Multiple Myeloma
Drug: Bortezomib
Drug: Daratumumab

Phase 3

Celgene
Celgene

Taipei, Taiwan and 256 other locations

combined with dexamethasone in subjects with relapsed or refractory multiple myeloma (RRMM) who received at least 2 prior lines of ...

Active, not recruiting
Multiple Myeloma in Relapse
Refractory Multiple Myeloma
Drug: TJ202 and Dexamethasone

Phase 2

TJ Biopharma Co., Ltd.

Taipei, Taiwan and 17 other locations

This study aims to evaluate alternative dosing regimens of single-agent belantamab mafodotin in participants with relapsed or refractory multiple...

Active, not recruiting
Multiple Myeloma
Drug: Belantamab mafodotin

Phase 2

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Taipei, Taiwan and 97 other locations

Elranatamab is a bispecific antibody: binding of elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells c...

Enrolling
Multiple Myeloma
Drug: Daratumumab
Drug: Dexamethasone

Phase 3

Pfizer
Pfizer

Taipei, Taiwan and 71 other locations

antibody, daratumumab, can provide more benefit to people with multiple myeloma compared to a combination therapy including daratum ...

Enrolling
Multiple Myeloma
Drug: Elranatamab
Drug: Pomalidomide

Phase 3

Pfizer
Pfizer

Taipei, Taiwan and 262 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems